Solid Biosciences Inc. (SLDB)

NASDAQ: SLDB · Real-Time Price · USD

3.040

-0.110 (-3.49%)

At close: Feb 4, 2025, 4:00 PM

3.014

-0.026 (-0.86%)

After-hours: Feb 4, 2025, 7:49 PM EST

-3.49% (1D)

Market Cap	121.46M
Revenue (ttm)	n/a
Net Income (ttm)	-102.44M
Shares Out	39.95M
EPS (ttm)	-2.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	444,506
Open	3.130
Previous Close	3.150
Day's Range	2.980 - 3.260
52-Week Range	2.920 - 15.050
Beta	2.01
Analysts	Strong Buy
Price Target	17.75 (+483.88%)
Earnings Date	Mar 12, 2025

About SLDB

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which help... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 26, 2018

Employees 88

Stock Exchange NASDAQ

Ticker Symbol SLDB

Website https://www.solidbio.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for SLDB stock is "Strong Buy." The 12-month stock price forecast is $17.75, which is an increase of 483.88% from the latest price.

Price Target

$17.75

(483.88% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to...

14 days ago - Seeking Alpha

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

- Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation -

14 days ago - GlobeNewsWire

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

- Duchenne : Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -

20 days ago - GlobeNewsWire

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

27 days ago - GlobeNewsWire

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia -

4 weeks ago - GlobeNewsWire

Solid Biosciences Added to the Nasdaq Biotechnology Index

CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

6 weeks ago - GlobeNewsWire

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).

7 weeks ago - Benzinga

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

2 months ago - GlobeNewsWire

Solid Biosciences to Present at the Jefferies London Healthcare Conference

CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

2 months ago - GlobeNewsWire

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 ...

3 months ago - GlobeNewsWire

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardia...

4 months ago - GlobeNewsWire

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscula...

5 months ago - GlobeNewsWire

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 202...

6 months ago - GlobeNewsWire

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardia...

7 months ago - GlobeNewsWire

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —

9 months ago - GlobeNewsWire

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024....

10 months ago - Seeking Alpha

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., Ap...

11 months ago - GlobeNewsWire